Zacks Research Issues Pessimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research reduced their Q3 2026 earnings estimates for shares of Corcept Therapeutics in a note issued to investors on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the biotechnology company will earn $0.21 per share for the quarter, down from their prior forecast of $0.30. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2028 earnings at $3.02 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same period in the previous year, the firm earned $0.26 earnings per share. The business’s quarterly revenue was up 11.1% on a year-over-year basis.

Several other equities research analysts also recently commented on CORT. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a report on Wednesday, December 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. HC Wainwright reduced their price target on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research note on Wednesday, December 31st. Finally, UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $77.17.

Corcept Therapeutics Stock Down 0.6%

Shares of NASDAQ:CORT opened at $33.30 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $117.33. The business’s 50 day simple moving average is $37.57 and its two-hundred day simple moving average is $62.37. The firm has a market cap of $3.54 billion, a P/E ratio of 40.61 and a beta of 0.29.

Insider Activity at Corcept Therapeutics

In other news, insider William Guyer sold 8,233 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total value of $296,305.67. Following the transaction, the insider owned 2,231 shares in the company, valued at $80,293.69. This trade represents a 78.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 48,233 shares of company stock valued at $1,817,306 over the last three months. Corporate insiders own 20.80% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors have recently bought and sold shares of CORT. Rockefeller Capital Management L.P. boosted its holdings in Corcept Therapeutics by 438.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 65,797 shares of the biotechnology company’s stock worth $2,290,000 after acquiring an additional 53,574 shares during the last quarter. Corient Private Wealth LLC grew its stake in shares of Corcept Therapeutics by 9.3% in the 4th quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock worth $245,000 after acquiring an additional 600 shares in the last quarter. SHP Wealth Management purchased a new stake in shares of Corcept Therapeutics in the fourth quarter valued at about $72,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Corcept Therapeutics in the fourth quarter valued at about $8,757,000. Finally, Virtu Financial LLC bought a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $456,000. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Lead‑plaintiff deadline: multiple firms remind investors that April 21, 2026 is the deadline to move for lead plaintiff in the pending securities class action — an immediate procedural date that could determine litigation leadership and the pace of the case. Robbins LLP Notice
• Negative Sentiment: Allegations of disclosure failures and regulatory/patent setbacks: Hagens Berman and others say the lawsuit stems from an alleged concealment of repeated FDA warnings about insufficient data and a federal court patent loss — claims that, if proven, could drive material damage awards or settlements and prolonged expense. Hagens Berman Alert
• Negative Sentiment: Multiple law firms soliciting clients: At least a dozen plaintiff firms (Robbins, Levi & Korsinsky, Rosen, Pomerantz, Kahn Swick & Foti, Glancy, Bronstein, Schall, Bernstein, Gross, et al.) have issued investor alerts and filings covering the Oct. 31, 2024–Dec. 30, 2025 class period — increasing the likelihood of a contested, high‑profile suit and amplification of reputational and financial risk. Kahn Swick & Foti / GlobeNewswire

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.